<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02795143</url>
  </required_header>
  <id_info>
    <org_study_id>2016P000845</org_study_id>
    <nct_id>NCT02795143</nct_id>
  </id_info>
  <brief_title>Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study</brief_title>
  <official_title>Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether isotretinoin is helpful in treating
      patients with an adverse cutaneous drug eruption known as toxic epidermal necrolysis (TEN).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Toxic epidermal necrolysis (TEN) is a potentially life-threatening skin disorder
      characterized by widespread redness, blistering and peeling of skin.

      Currently, supportive care in the standard treatment for patients with TEN. Isotretinoin, an
      FDA-approved medication commonly used for treating severe acne induces differentiation of
      certain inflammatory cells and thus may potentially be helpful in treating patients with TEN.

      This is a randomized, placebo-controlled, double-blind, pilot study comparing the efficacy
      and safety of isotretinoin versus placebo in treating subjects with toxic epidermal
      necrolysis (TEN).

      Approximately 40 subjects who satisfy all inclusion and exclusion criteria will be randomly
      assigned in a 1:1 ratio to either isotretinoin or placebo which they will take for up to 14
      days. The end of the study is defined as the time the subject is discharged from the
      hospital. Participants will primarily be assessed for percent body surface affected (BSA) and
      number of days of hospitalization.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of days of hospitalization</measure>
    <time_frame>up to 14 days</time_frame>
    <description>Number of days patient will be hospitalized.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of body surface affected (BSA)</measure>
    <time_frame>up to 14 days</time_frame>
    <description>Maximum body surface affected with TEN.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Toxic Epidermal Necrolysis</condition>
  <arm_group>
    <arm_group_label>Isotretinoin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isotretinoin will be given at the following dosage:
Dosing will be as listed on the table below.
Weight in Kg Total Daily Dose 40-49 Kg 40mg 50-89 Kg 80mg 90-150 Kg 120mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be given placebo capsules twice a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotretinoin</intervention_name>
    <arm_group_label>Isotretinoin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 - 69 years of age

          2. Has biopsy-proven toxic epidermal necrolysis (TEN)

          3. If female, should not be of childbearing potential defined as:

               -  Have not had menstrual periods for 12 months in a row (menopause) OR

               -  Had bilateral oophorectomy or total hysterectomy OR

               -  Have a ovarian disorder that would make pregnancy not possible

        Exclusion Criteria:

          1. Unknown HIV status and unwilling to undergo HIV testing

          2. Women of childbearing potential

          3. Pregnancy

          4. Breastfeeding

          5. Fasting serum triglyceride levels &gt;25% of upper limit of normal

          6. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline
             phosphatase levels &gt;2Ã— upper limit of normal (ULN)

          7. Known allergy to isotretinoin

          8. History of suicidal attempt, psychosis, major depression or other serious mood
             disorders

          9. Currently taking vitamin A supplements, tetracyclines, phenytoin, corticosteroids,
             IVIg or St. John's Wort

         10. Has any condition that, in the opinion of the investigator, would make participation
             not be in the best interest (for example, compromise the well-being) of the
             participant or that could prevent, limit, or confound the protocol-specified
             assessments

         11. Participation in an interventional study within the past 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arturo Saavedra, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arturo Saavedra, MD, PhD</last_name>
    <phone>617-726-5066</phone>
    <email>harvardskinstudies@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arturo Saavedra, MD, MBA</last_name>
      <phone>617-726-5066</phone>
      <email>asaavedra@partners.org</email>
    </contact>
    <investigator>
      <last_name>Arturo Saavedra, MD, MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2016</study_first_submitted>
  <study_first_submitted_qc>June 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2016</study_first_posted>
  <last_update_submitted>December 5, 2016</last_update_submitted>
  <last_update_submitted_qc>December 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Arturo P Saavedra</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>TEN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stevens-Johnson Syndrome</mesh_term>
    <mesh_term>Drug Eruptions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

